glp 1 agonist review article Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic and Meta-Analysis GLP-1 receptor agonists show promise

Specifically, after 30 weeks, 36.7% of patients receiving exenatide twice-daily were antibody-positive

The medication isnt perfect

Pharmacists are well suited to advocate for optimal patient care by recommending appropriate agents on the basis of patient-specific considerations and providing appropriate education to people living with T2D

Although SGLT-2 inhibitors have not been noticeably associated with SUD outcomes, the observed effect represents the causal contrast between these two specific drug classes, which may differ from the contrast with another comparator or placebo

Both direct and indirect modes of action are possible, including better blood glucose regulation, weight loss, and cardioprotective and renoprotective effects